GNMSF - 3 Things In Biotech May 26: Immunotherapy Strikes Lung Cancer Yet Again
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research.
AstraZeneca marks a new historic achievement in competitive lung cancer space
Company: AstraZeneca (AZN)
Therapy: Durvalumab
Disease: Non-small cell lung cancer (NSCLC)
News: AZN announced that the phase 3 PACIFIC trial has met its second primary endpoint, overall survival. Durvalumab given after definitive chemoradiation therapy for stage III NSCLC provides a survival benefit for patients. This builds on the original publication of